The study reported higher radionuclide signal intensity with 68Ga-NOTA-GZP in tumor with combination treatment of anti-CTLA-4 and anti-PD-1 antibodies, compared to mono immune checkpoint therapy and untreated mice. This evidence concerns the gene CTLA4 and neoplasm.